Tryptamine Therapeutics Limited
TYPTF
$0.01
$0.00-6.67%
OTC PK
| 03/31/2025 | 12/31/2024 | 12/31/2024 | 09/30/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 55.19% | -54.31% | -54.31% | -6.36% | 29.88% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 213.49% | -318.75% | -318.75% | -213.05% | 10.67% |
| Change in Net Operating Assets | -6,879.20% | -- | -- | -- | -103.44% |
| Cash from Operations | 30.84% | -130.91% | -130.91% | -100.73% | 1.43% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,394.56% | -57.43% | -57.43% | 522.42% | -- |
| Foreign Exchange rate Adjustments | -1,600.00% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.07% | -165.48% | -165.48% | -19.29% | 272.76% |